November 26, 2014
CHICAGO — At 20 years, men assigned statin therapy during the 5-year West of Scotland Coronary Prevention Study had lower rates for mortality and CV events compared with men assigned placebo, regardless of whether they continued taking statins, according to findings presented at the American Heart Association Scientific Sessions.
From 1989 to 1995, researchers randomly assigned 6,595 men aged 45 to 64 years to pravastatin 40 mg/day or placebo. For the original West of Scotland Coronary Prevention Study (WOSCOPS), they remained randomly assigned for 5 years. After the initial 5-year period, in which the pravastatin group had LDL lowered by approximately 20% more than the placebo group, participants continued to be followed, but their general practitioners decided whether to initiate or continue statin therapy. An interim analysis had found that after the original trial, statin usage was equal in both treatment arms, with 31% of men in both groups using statins.